Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Polynovo Ltd (ASX: PNV) is an Australian-based medical device company that designs, develops and manufactures dermal regeneration solutions.
Its flagship patented NovoSorb biodegradable polymer technology is used to develop innovative medical devices that help surgeons treat patients with traumatic wounds. The company also has a development program covering breast sling, hernia, and orthopaedic applications.
Investors in the Polynovo share price will be happy to know the company is preparing for growth by expanding its manufacturing facility and headquarters in Melbourne, and establishing high quality processes that enable product innovation.
|22 Oct 2021||$1.85||$-0.03||-1.60%||2,345,783||$1.87||$1.92||$1.85|
|21 Oct 2021||$1.87||$0.00||0.00%||2,403,762||$1.90||$1.94||$1.87|
|20 Oct 2021||$1.87||$0.01||0.54%||3,311,924||$1.89||$1.93||$1.86|
|19 Oct 2021||$1.87||$0.07||3.89%||1,396,602||$1.78||$1.88||$1.78|
|18 Oct 2021||$1.80||$-0.05||-2.70%||1,136,152||$1.86||$1.86||$1.79|
|15 Oct 2021||$1.86||$0.07||3.91%||1,975,927||$1.82||$1.87||$1.80|
|14 Oct 2021||$1.79||$0.06||3.47%||1,534,923||$1.75||$1.80||$1.74|
|13 Oct 2021||$1.73||$0.01||0.58%||1,079,552||$1.72||$1.76||$1.72|
|12 Oct 2021||$1.72||$-0.05||-2.83%||1,613,621||$1.76||$1.77||$1.71|
|11 Oct 2021||$1.77||$0.01||0.57%||1,975,046||$1.75||$1.78||$1.73|
|08 Oct 2021||$1.76||$0.02||1.16%||1,472,574||$1.74||$1.77||$1.73|
|07 Oct 2021||$1.73||$0.08||4.85%||2,296,607||$1.67||$1.75||$1.67|
|06 Oct 2021||$1.65||$-0.11||-6.27%||6,297,238||$1.76||$1.78||$1.65|
|05 Oct 2021||$1.76||$-0.05||-2.77%||3,912,608||$1.80||$1.81||$1.73|
|04 Oct 2021||$1.81||$-0.05||-2.70%||2,421,959||$1.85||$1.87||$1.80|
|01 Oct 2021||$1.85||$-0.08||-4.16%||2,016,569||$1.90||$1.92||$1.85|
|30 Sep 2021||$1.93||$0.03||1.58%||2,246,929||$1.88||$1.93||$1.87|
|29 Sep 2021||$1.90||$0.02||1.06%||3,149,078||$1.85||$1.90||$1.81|
|28 Sep 2021||$1.88||$-0.09||-4.58%||2,410,372||$1.95||$1.95||$1.88|
|27 Sep 2021||$1.97||$0.01||0.51%||1,111,815||$1.96||$2.01||$1.95|
|24 Sep 2021||$1.96||$-0.04||-2.00%||1,365,301||$2.01||$2.01||$1.95|
|23 Sep 2021||$2.00||$0.04||2.04%||1,827,941||$1.97||$2.01||$1.97|
|26 Mar 2021||Bruce Rathie||Sell||200||$571,220|| |
|09 Mar 2021||David Williams||Buy||100||$234,000|| |
|04 Mar 2021||David Williams||Buy||300||$721,198|| |
|02 Dec 2020||Leon Hoare||Sell||100||$345,400|| |
On-market trade. As per announcement on 02/12/2020.
|01 Dec 2020||Bruce Rathie||Sell||355||$1,194,478|| |
|01 Dec 2020||Paul Brennan||Sell||200||$678,000|| |
On-market trade. As per announcement on 01/12/2020.
|Mr David Williams||Non-Executive DirectorNon-Executive Chairman||Feb 2014|| |
Mr Williams is an experienced Director and investment banker with a track record in business development as well as in mergers and acquisitions and capital raising. He has 30+ years experience working with and advising ASX-listed companies in the food, medical device, and pharmaceutical sectors. Mr Williams is currently Chairman of RMA Global Limited and is Managing Director of corporate advisory firm Kidder Williams Ltd.
|Mr Bruce Rathie||Non-Executive Director||Feb 2010|| |
Mr Rathie is an experienced Company Director with a finance and legal background. He practised as a partner in a large legal firm and acted as Senior Corporate Counsel to Bell Resources Limited in its early years. He has a 15-year investment banking career. When Head of the Industrial Franchise Group at Salomon Smith Barney he led Salomon's roles in the Federal Government's privatisation of Qantas, Commonwealth Bank (CBA3) and Telstra (T1). He now has over 20 years experience as a full time professional Nonexecutive Director. He is currently Chairman of Capricorn Mutual Limited and a Non-executive Director of Capricorn Society Limited and Australian Meat Processors Limited. In the medical device space, he was previously Director of Compumedics Limited and USCOM Limited.
|Mr Paul Brennan||Managing Director||Feb 2015|| |
Mr Brennan has knowledge, exposure and understanding of the health system through his clinical background and commercial exposure with various multinational companies. He has coordinated the marketing, global strategy development, new product development and regulatory processes for the Asia- Pacific region for industry-leading organisations in relation to medical products and devices. Mr Brennan has knowledge of the manufacturing and production processes. Previously he was Marketing Director Australia and New Zealand and Sales Director New Zealand for Smith & Nephew Healthcare from 2008 to his commencement with PolyNovo in February 2015.
|Dr Robyn Elliott||Non-Executive Director||Oct 2019|| |
Dr Elliott is currently Executive Director, Strategic Fractionation Program Delivery at CSL Behring, a global role that is responsible for business value delivery from a billion-dollar capital expansion portfolio. Dr Elliott previously held Strategic Expansion and Quality Senior Director roles within CSL, was the Managing Director at IDT Australia and commenced her career at DBL Faulding. Dr Elliott has a proven track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategy, regulatory affairs and audit will be invaluable to PolyNovo as the company scales its operations globally.
|Dr David McQuillan||Non-Executive Director||Aug 2012|| |
Dr McQuillan has technical, medical, scientific, and regulatory knowledge, as well as merger and acquisition expertise. Dr McQuillan was with LifeCell Inc/Kinetic Concepts Inc (KCI) for 12 years, holding a number of senior roles, including Vice President for Research and Development at LifeCell and Senior Vice President of Advanced Research and Technology at KCI. He was Chief Science Officer for TELA Bio, a VC-funded development stage biotechnology company from 2013 to 2015. He is currently a Non-executive Director for Cell Care Therapeutics Inc (a privately held stem cell company based in Monrovia, CA) and Nonexecutive Director and Co-Founder of ECM Technologies Inc (a privately held biotechnology company based in Houston, TX).
|Mr Andrew Stuart Lumsden||Non-Executive Director||Jun 2021|| |
Mr Lumsden is a Chartered Accountant and finance executive with more than 20 years experience locally and internationally. Mr Lumsden is currently Global Chief Operating Officer of Wellcom Group Pty Ltd (formerly Wellcom Group Limited) having previously held the roles of Chief Financial Officer and Company Secretary. Prior to joining Wellcom, Mr Lumsden was a Senior Manager within the Audit and Assurance practice of PricewaterhouseCoopers.
|Mr Leon Hoare||Non-Executive Director||Jan 2016|| |
Mr Hoare is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew ANZ (all divisions) until 2015, one of Smith & Nephew's largest global subsidiaries outside the USA. He served as President of Smith & Nephew's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division. In his 24 years with Smith & Nephew, he also held roles in marketing, divisional and general management. His career has also included a senior role at Bristol-Myers Squibb (medical devices), and as Vice Chair of Australia's peak medical device body, Medical Technology Association of Australia.
|Ms Christine Emmanuel||Non-Executive Director||May 2020|| |
Ms Emmanuel is a patent and trademark attorney, and a business development professional with more than 30 years local and international experience. She is Vice President of the Board of the Institute of Patent and Trade Mark Attorneys of Australia on Springboard Enterprises Life Sciences Council, is a non-executive director on the board of Medical Developments International. Ms Emmanuel is currently IP & Commercialisation manager at RMIT University and was previously Executive Manager of Business Development and Commercial at the CSIRO, having founded and led the management of CSIRO's IP portfolio for over 10 years and managed the growth of the CSIRO equity portfolio for the last 5 years. Previously she was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK) and Davies Collison
|Mr Jan-Marcel Gielen||Chief Financial OfficerCompany Secretary||Dec 2018|| |
|Jan-Marcel Gielen||Chief Financial OfficerCompany Secretary|| |
|Anthony Kaye||Chief Operating Officer|| |
|HSBC Custody Nominees (Australia) Limited||86,192,215||13.03%|
|J P Morgan Nominees Australia Pty Limited||41,780,382||6.32%|
|Citicorp Nominees Pty Limited||27,212,802||4.11%|
|Moggs Creek Pty Ltd <Moggs Creek Super A/C>||17,800,000||2.69%|
|National Nominees Limited||16,084,276||2.43%|
|Lateral Innovations Pty Ltd <Trust A/C>||10,924,103||1.65%|
|Mr Anthony Shane Kittel + Mrs Michele Therese Kittel <Kittel Family Super A/C>||7,960,000||1.20%|
|BNP Paribas Noms Pty Ltd <Drp>||7,944,172||1.20%|
|BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>||6,340,183||0.96%|
|BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C>||5,300,974||0.80%|
|Mr Paul Gerard Brennan||4,185,095||0.63%|
|Ms Simone Maree Beks||4,185,095||0.63%|
|Commonwealth Scientific And Industrial Research Organisation||4,081,250||0.62%|
|Netwealth Investments Limited <Wrap Services A/C>||4,019,409||0.61%|
|BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C>||3,397,939||0.51%|
|Sandhurst Trustees Ltd <Endeavor Asset Mgmt Mda A/C>||3,374,840||0.51%|
|Mr Paul Lappin + Mrs Siobhan Lyons <Lappin Super Fund A/C>||3,154,631||0.48%|
|Mr David Kenley||3,139,855||0.47%|
|Dr Marcus James Dermot Wagstaff + Mrs Lara Kate Wagstaff||3,056,377||0.46%|
|Mr Laurent Fossaert||3,014,172||0.46%|